Lifecore Biomedical Inc (LFCR) Stock Analysis
Verdict: AVOID
Lifecore's high debt load and negative equity overshadow CDMO volume gains, leaving the stock vulnerable after a single-day rally.
Investment score: 34/100
Analysis as of
Is Lifecore Biomedical Inc stock worth reviewing? The TradeMates thesis
The model flags Lifecore Biomedical as a high-risk speculative profile due to negative equity, $142.6M in debt, and a single-day +55.2% rally that pushed the price above analyst consensus targets.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 30/100 (weight 15%)
- Technical Momentum: 65/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 30/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Lifecore Biomedical Inc opportunities and risks
What speaks for LFCR
- CDMO Capacity Expansion and Hyaluronic Acid Demand
What speaks against LFCR
- Negative Stockholders' Equity and Restructuring Risk
Frequently asked questions about Lifecore Biomedical Inc (LFCR)
Is LFCR stock a good investment?
The TradeMates model rates Lifecore Biomedical Inc as AVOID with an investment score of 34/100. The model flags Lifecore Biomedical as a high-risk speculative profile due to negative equity, $142.6M in debt, and a single-day +55.2% rally that pushed the price above analyst consensus targets. This is algorithmic model output, not personal investment advice.
Is LFCR stock a buy?
The TradeMates model verdict for LFCR is AVOID with an investment score of 34/100. Treat this as a model signal to review, not a personal buy recommendation.